HLTH / Cue Health CEO on FDA emergency authorization for Covid at-home test

Cue Health Inc. (NASDAQ:HLTH ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Lorna Williams - IR Ayub Khattak - Co-F more_horizontal

Cue Health Inc. (HLTH) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss more_horizontal

The U.S. Food and Drug Administration on Tuesday approved Cue Health's at-home COVID-19 test, the first coronavirus test to get marketing authorizatio more_horizontal

Cue Health Inc. (HLTH) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to t more_horizontal

Cue Health Inc. (HLTH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). more_horizontal

Cue Health Inc. (HLTH) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with more_horizontal

Cue Health, Inc. (NASDAQ:HLTH ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Lorna Williams - IR Ayub Khattak - Co-Fo more_horizontal

SAN DIEGO--(BUSINESS WIRE)--Cue Health Inc. (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that it will release its firs more_horizontal